Ivor

Bemiparin Sodium, the active ingredient in Ivor, is a low molecular weight heparin presented as a subcutaneous formulation for injection use. It is employed to prevent and treat venous thromboembolic disorders in surgical, medical and high‑risk patient populations.

GNH USA supplies Ivor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bemiparin Sodium acts as an anticoagulant in the venous thromboembolism pathway, reducing clot formation in several clinical settings.

- Prevention of venous thromboembolism in surgical patients: lowers the risk of postoperative deep vein thrombosis and pulmonary embolism. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension. - Prevention of pulmonary embolism: reduces incidence of embolic events in at‑risk individuals. - Prophylaxis of thromboembolic events in high‑risk medical patients: provides anticoagulation for immobile or critically ill patients.

Adverse reactions may occur with Bemiparin Sodium use. Patients should be monitored for any signs of bleeding or hypersensitivity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Bruising or hematoma: localized bleeding under the skin. - Nausea or vomiting: gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness. - Mild bleeding gums: occasional oral bleeding.

Serious or Rare Side Effects: - Heparin‑induced thrombocytopenia (HIT): sudden drop in platelet count. - Major bleeding: gastrointestinal or intracranial hemorrhage. - Spinal or epidural hematoma: bleeding in the spinal canal. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Elevated liver enzymes: abnormal hepatic function tests. - Paradoxical thrombosis: new clot formation despite therapy.

Careful assessment and monitoring are essential when using Bemiparin Sodium to minimize risks.

- Renal impairment: adjust therapy and monitor renal function. - Hepatic impairment: evaluate liver function before initiation. - Concomitant anticoagulants or antiplatelet agents: increase bleeding risk; use with caution. - Recent surgery or trauma: assess bleeding risk before administration. - Pregnancy and breastfeeding: safety not established; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Bemiparin Sodium may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulant effect. - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding risk. - Thrombolytic therapy (e.g., alteplase): increased hemorrhagic complications. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates bleeding. - Spinal or epidural anesthesia: risk of hematoma formation.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency. - Corticosteroids: potential for gastrointestinal bleeding. - Renal‑clearing drugs (e.g., aminoglycosides): monitor renal function. - Herbal supplements with antiplatelet activity (e.g., ginkgo, garlic): observe for signs of bleeding. - ACE inhibitors: watch for rare synergistic effects on coagulation.